Pneumologie

Economic Burden of Severe Asthma With Omalizumab

Economic Burden of Severe Asthma in Adults and Children Treated With Omalizumab From 2012 to 2019

INTRODUCTION

Uncontrolled asthma is a condition associated with high morbidity and healthcare costs. We described healthcare resource use (HCRU) and related costs in asthma adults and children treated with omalizumab (OMA) before and after OMA initiation (T0)..

find the whole article here ==>https://doi.org/10.1016/j.jval.2022.09.261

Authors
A Bourdin
A Deschildre
M Humbert
R Niarra
C Thonnelier
M Laborey
A Lajoinie
A Bernard
M Molimard
C Taillé

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

pneumologie
Actualités RCTS - Publications - Pneumologie

Real-life triple therapy COPD: The Trilife study

Real-life omalizumab exposure and discontinuation
Pneumologie

Real-life omalizumab exposure and discontinuation

Persistence and Patterns of Exposure to Omalizumab
Pneumologie

Persistence and Patterns of Exposure to Omalizumab